Expertise in
18
conditions

Julien Seneschal

Bordeaux, FR 
Expertise in
18
conditions
Bordeaux, FR 

Overview

Julien Seneschal practices practicing medicine in Bordeaux, France.

Mr. Seneschal is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Vitiligo, Hypomelanotic Disorder, Atopic Dermatitis, and Alopecia Areata.

He is actively involved in clinical research, co-authoring 255 peer reviewed articles and participating in 13 clinical trials.

Gender

Male

Locations

Bordeaux, France
Other Locations
Talence, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Soluble CD95 Ligand Role in the Pathophysiology of ANCA Associated Vasculitis
Soluble CD95 Ligand Role in the Pathophysiology of ANCA Associated Vasculitis
Enrollment Status: Completed
Publish Date: August 17, 2026
Intervention Type: Biological
Study Phase: Not Applicable
Evaluation of Effect and Tolerance of the Association of Baricitinib (4 mg) and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo: a Randomized, Double-blind, Prospective, Non-comparative Phase II Study.
Evaluation of Effect and Tolerance of the Association of Baricitinib (4 mg) and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo: a Randomized, Double-blind, Prospective, Non-comparative Phase II Study.
Enrollment Status: Completed
Publish Date: June 12, 2026
Intervention Type: Drug
Study Drug: Baricitinib Oral Product
Study Phase: Phase 2
Efficacy and Tolerance of the Combination of Methotrexate and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo: a Randomized Double-blind Prospective Study
Efficacy and Tolerance of the Combination of Methotrexate and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo: a Randomized Double-blind Prospective Study
Enrollment Status: Completed
Publish Date: May 22, 2026
Intervention Type: Drug
Study Drug: Methotrexate
Study Phase: Phase 2
Vasculopathy, Inflammation and Systemic Sclerosis: The Role of Endothelial Cell Activation and OX40/OX40L in Modulation of T Lymphocyte Activation
Vasculopathy, Inflammation and Systemic Sclerosis: The Role of Endothelial Cell Activation and OX40/OX40L in Modulation of T Lymphocyte Activation
Enrollment Status: Completed
Publish Date: May 14, 2026
Intervention Type: Biological
Study Phase: Not Applicable
Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis
Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis
Enrollment Status: Completed
Publish Date: May 14, 2026
Intervention Type: Biological
Study Phase: Not Applicable
Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular Diseases
Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular Diseases
Enrollment Status: Active_not_recruiting
Publish Date: February 03, 2026
Intervention Type: Biological, Other, Behavioral
Study Phase: Not Applicable
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
DUPECZEMAIN : Double Blind Placebo-controlled Randomized Multicenter Study Assessing the Efficacy and Safety of Dupilumab in Moderate to Severe Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids
DUPECZEMAIN : Double Blind Placebo-controlled Randomized Multicenter Study Assessing the Efficacy and Safety of Dupilumab in Moderate to Severe Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids
Enrollment Status: Completed
Publish Date: December 03, 2024
Intervention Type: Drug
Study Drug: Dupilumab
Study Phase: Phase 2
A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis
A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine
Enrollment Status: Completed
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drugs: Baricitinib, Corticosteroid
Study Phase: Phase 3
View 9 Less Clinical Trials

255 Total Publications

Rapid efficacy of anifrolumab in refractory cutaneous dermatomyositis.
Rapid efficacy of anifrolumab in refractory cutaneous dermatomyositis.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: May 22, 2026

Frequently Asked Questions about Julien Seneschal

Is Julien Seneschal a top-rated expert for Vitiligo?

MediFind is an objective health platform that identifies experts based on real-world data. Julien Seneschal is classified as an Elite expert for Vitiligo, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Julien Seneschal participate in research or clinical trials?

Yes. Julien Seneschal has published 255 articles and abstracts on conditions like Vitiligo. You can view a list of Julien Seneschal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Seneschal's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 37 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile